Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAR444836 gene therapy in adult phenylketonuria
NCT05972629Phase 2Active, not recruiting
- Sponsor
- Sanofi
- Start
- Aug 2023
- Primary completion
- Apr 2030
- Modality
- Gene Editing, Gene Silencing, AAV Vectors
- Countries
- 5
01
Overview
A Phase 2 trial of SAR444836 in phenylketonuria (PKU), sponsored by Sanofi. Started Aug 2023; status: active, not recruiting.
02
Drugs
SAR444836
03
Conditions
phenylketonuria (PKU)
Beyond the preview
Go deeper on NCT05972629.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05972629.